Total
0
Shares
Immutep (ASX:IMM) - CEO, Marc Voigt - The Market Herald
CEO, Marc Voigt
Source: Finance News Network
  • Biotech company Immutep (IMM) has received €2,173,454 (roughly A$3.6 million) from the French Government
  • The funds come from a research and development (R&D) tax incentive payment
  • The French Research Tax Credit gives a 30 per cent reimbursement to French companies for research and development activities in Europe
  • Immutep qualifies to receive the tax incentive through its subsidiary, which has a laboratory in southwest Paris
  • Funds from the incentive will be used to support Immutep's metastatic breast cancer treatment and the development of its IMP761 drug for autoimmune diseases
  • Immutep is up 1.08 per cent on the market this morning, selling shares for 19 cents each

Biotech company, Immutep (IMM) has received $3.6 million (€2,173,454) from the French Government.

The funds come from a research and development (R&D) tax incentive payment, under Immutep's Crédit d’Impôt Recherche (CIR) scheme.

Crédit d’Impôt Recherche means Research Tax Credit and is a French Government tax incentive, which gives a 30 per cent reimbursement to French companies for research and development activities in Europe.

Immutep qualifies to receive the tax incentive through its subsidiary, Immutep S.A.S., as it has a laboratory at Châtenay-Malabry in southwest Paris.

Funds from the incentive will be used to support Immutep's metastatic breast cancer treatment and the development of its IMP761 drug for autoimmune diseases.

The former treatment, efti, is an anti-cancer drug that is designed to treat the most advanced stage of breast cancer. Earlier this month, efti was granted a patent from the Japanese Patent Office.

Immutep is up 1.08 per cent on the market this morning, selling shares for 19 cents each at 11:06 am AEST.


Subscribe


IMM by the numbers
More From The Market Herald
Telix Pharmaceuticals (ASX:TLX)- CEO, Dr. Christian Behrenbruch - The Market Herald

" Telix Pharmaceuticals (ASX:TLX) submits NDA for prostate cancer imaging product

Telix Pharmaceuticals (TLX) has submitted a new drug application (NDA) with the U.S.
Recce Pharmaceuticals (ASX:RCE) completes $27.95M capital raise

" Recce Pharmaceuticals (ASX:RCE) completes $27.95M capital raise

Recce Pharmaceuticals (RCE) has completed its capital raise and successfully raised $27.95 million.
Cynata Therapeutics (ASX:CYP) - Managing Director & CEO, Dr Ross Macdonald - The Market Herald

" Cynata Therapeutics (ASX:CYP) receives positive results for stem cell treatment in heart attack

Cynata Therapeutics (CYP) has received positive results for its Cymerus stem cell treatment in a preclinical heart attack model.
PharmaAust Limited (ASX:PAA) - Executive Chairman, Dr Roger Aston - The Market Herald

" PharmAust (ASX:PAA) advances testing against COVID-19

PharmAust (PAA) has advanced its monepantel drugs testing against COVID-19, in the race to find a vaccine for the virus.